Most Recent Articles
Ninety percent of patients with ALL who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019.
John M. “Jack” Flynn, MD, a nationally prominent specialist in pediatric orthopedic surgery, was recently appointed chief of The Children’s Hospital of Philadelphia’s Division of Orthopedics.
Researchers rarely use the word "cure" when studying a rare disease with no approved therapies. At the Friedreich's Ataxia Center of Excellence, the word "cure" is now in the lexicon.
Read a case study about a previously healthy 12-year-old boy presented to CHOP Urgent Care with fever and nonproductive cough.
The Newborn and Infant Chronic Lung Disease Program at The Children’s Hospital of Philadelphia (CHOP) is one of the largest programs of its kind in the world.
This is the case of a 15-year-old boy who had suffered night blindness since early childhood and had been clinically diagnosed with retinitis pigmentosa (RP).